Biocon enters into pact with CMS to sell 3 generic products in China

Biocon on September 12 said it has signed a license and supply agreement with a subsidiary of China Medical System Holdings (CMS) for three generic formulation products in Greater China. Biocon, however, has not specified which products are going to be part of this deal. Under the terms of the agreement, Biocon will be responsible for the development, manufacturing and supply of the products while CMS will be responsible for registration and commercialisation of the products in China. The initial term of the agreement shall be for 10 years from the date…

Read More